Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
High titer human convalescent plasma will be extracted from apheresis donations from twenty recently-sick and currently-recovered COVID-19 patients. An open-label, phase 2A clinical trial will then be conducted to administer convalescent plasma to twenty individuals with confirmed cases of COVID-19 to investigate the novel application of convalescent plasma in the treatment strategy of SARS-CoV-2.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be 18 years of age or older
Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing. Patient is willing and able to provide written informed consent and comply with all protocol requirements.
Patient agrees to storage of specimens for future testing.
You may not be if
Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period
Receipt of pooled immunoglobulin in past 30 days
Contraindication to transfusion or history of prior reactions to transfusion blood products
Clareo Health | Convalescent Plasma to Limit Coronavirus Associated Complications
